Lanean...

Use of class I histone deacetylase inhibitor romidepsin in combination regimens

Histone deacetylase (HDAC) inhibitors are epigenetic-modifying agents that have shown promise as anticancer therapies. Several HDAC inhibitors have been approved by the US Food and Drug Administration (FDA) as single-agent therapies to treat T-cell lymphoma. The synergistic combination of HDAC inhib...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Leuk Lymphoma
Egile Nagusiak: Petrich, Adam, Nabhan, Chadi
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2016
Gaiak:
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4950458/
https://ncbi.nlm.nih.gov/pubmed/27118119
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2016.1160082
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!